

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Imagion Biosystems Limited
<b>ABN</b> 42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mark Gerald Van Asten
<b>Date of last notice</b>	28 April 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	20 May 2024
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. 613,125 Ordinary Shares</li> <li>2. 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>3. 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> </ol>
<b>Class</b>	Fully Paid Ordinary Shares Unlisted Options
<b>Number acquired</b>	N/A
<b>Number disposed</b>	N/A

---

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	N/A
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 15,329 Ordinary Shares</li> <li>2. 6,250 Unlisted Performance Options (exercisable at \$1.12, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>3. 3) 6,250 Unlisted Performance Options (exercisable at \$1.12, vesting on 1 May 2022, expiring 1 May 2027)</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The Appendix 3Y reflects changes resulting from share consolidation only on the basis that every forty (40) securities will be consolidated to one (1) security at the 13 November 2023 Extraordinary General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.